Press-release for stocks related to cancer for astrazeneca plc

tags : Cancer entities : Astrazeneca plc

save search

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 0.88% | O: -1.18% H: 0.34% C: -0.22%
breast her2 license cancer application negative

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
Published: 2024-03-19 (Crawled : 12:00) - biospace.com/
FUSN | $21.26 0.05% 0.05% 440K

Health Technology

| 99.81% | O: 96.99% H: 1.19% C: 1.05%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 4.1% | O: -0.38% H: 0.46% C: 0.4%
astrazeneca cancer treat acquire

GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Published: 2024-03-18 (Crawled : 13:30) - biospace.com/
ILMN | $117.43 0.63% 0.63% 1.4M

Health Technology

| -8.06% | O: 0.51% H: 2.49% C: 1.37%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 3.38% | O: -0.45% H: 0.55% C: -0.24%
lung test cancer risk study

Cervical Cancer Global Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Published: 2024-03-01 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -2.32% | O: 0.01% H: 0.0% C: -0.43%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 7.56% | O: 0.59% H: 2.06% C: 2.06%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.52% | O: -1.27% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 6.84% | O: 0.28% H: 0.75% C: 0.4%
review cancer trials global trial

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 7.24% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $63.676 -4.38% 7.2K

Manufacturing

| 26.78% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | $9.47 -1.11% 520K

Manufacturing

| -14.57% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -10.18% | O: -0.2% H: 0.14% C: -0.48%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -8.0% | O: -0.06% H: 0.46% C: 0.29%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| -5.22% | O: -0.69% H: 1.42% C: 1.22%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| -2.63% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -3.89% | O: -0.65% H: 1.63% C: 1.48%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| -5.63% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -1.76% | O: 1.67% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 5.32% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| -5.13% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

9.18% CAGR growth in Cancer Biologics Market by Product (Monoclonal antibodies, Cell and gene therapy, vaccines, and others), Route Of Administration, and Geography- Global forecast to 2028
Published: 2024-02-19 (Crawled : 16:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M

Health Technology

| Email alert Add to watchlist
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| Email alert Add to watchlist
NVSEF | $93.6375 6.88% 82K

Health Technology

| Email alert Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| Email alert Add to watchlist
GLAXF | News | $20.2 -14.18% 510

Health Technology

| Email alert Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| Email alert Add to watchlist
AZNCF | News | $138.24 -4.19% 800

Health Technology

| Email alert Add to watchlist
JAZZ | $109.96 0.63% 0.63% 760K

Health Technology

| Email alert Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| Email alert Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| Email alert Add to watchlist
cancer cell global growth market

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-02-19 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| Email alert Add to watchlist
lung license cancer cell application advanced

Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K

Health Technology

| -12.32% | O: -1.53% H: 0.0% C: 0.0%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 1.76% | O: -0.37% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -8.98% | O: 0.41% H: 0.0% C: 0.0%
UCBJY | $63.676 -4.38% 7.2K

Manufacturing

| 38.0% | O: 1.71% H: 1.28% C: 0.94%
ALPMY | $9.47 -1.11% 520K

Manufacturing

| -12.76% | O: 0.28% H: 0.18% C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -6.5% | O: 0.07% H: 0.42% C: 0.07%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -9.04% | O: 0.09% H: 0.39% C: -0.36%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -5.03% | O: 1.47% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 3.02% | O: 0.76% H: 4.31% C: 2.11%
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -0.67% | O: -0.14% H: 0.35% C: -1.12%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| -2.7% | O: 1.48% H: 0.0% C: 0.0%
VRTX | News | $394.43 0.24% 0.24% 1.3M

Health Technology

| -5.25% | O: 0.15% H: 2.4% C: 0.56%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -0.49% | O: 1.33% H: 0.0% C: 0.0%
JAZZ | $109.96 0.63% 0.63% 760K

Health Technology

| -11.84% | O: -0.02% H: 0.0% C: -1.4%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 2.25% | O: -0.4% H: 0.19% C: -0.33%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| -14.91% | O: -0.18% H: 0.0% C: -6.22%
report cancer blood growth market

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 3.26% | O: -0.17% H: 0.09% C: -2.76%
GNPX | $2.2194 -2.31% 38K

Health Technology

| -63.96% | O: 33.84% H: 1.01% C: -15.3%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 4.43% | O: -0.76% H: 0.77% C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study

Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

Health Technology

| 4.69% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 3.77% | O: 3.41% H: 0.0% C: -2.45%
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| -4.74% | O: -0.08% H: 3.47% C: -0.25%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -12.43% | O: -2.04% H: 0.19% C: -1.97%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| 1.69% | O: 4.04% H: 1.57% C: -3.02%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 0.9% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.9% | O: 1.75% H: 0.0% C: 0.0%
PBYI | $5.01 0.4% 0.4% 290K

Health Technology

| 5.14% | O: -0.1% H: 2.31% C: -1.26%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 2.01% | O: 0.82% H: 0.12% C: -1.64%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| -14.52% | O: 0.44% H: 0.2% C: -0.55%
drug breast expected cancer pipeline therapeutics growth market

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2024-01-08 (Crawled : 12:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K

Health Technology

| 30.86% | O: 2.29% H: 8.38% C: 4.47%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 0.25% | O: 0.28% H: 0.99% C: 0.93%
first million payment astrazeneca cancer trial milestone

Cancer Immunotherapy Market to grow by USD 38.57 billion from 2022 to 2027, North America to account for 41% of market growth- Technavio
Published: 2024-01-04 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

Health Technology

| 3.48% | O: 2.46% H: 0.0% C: 0.0%
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -8.98% | O: 0.49% H: 0.6% C: -0.83%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| -0.62% | O: 0.15% H: 1.88% C: -1.17%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -10.82% | O: -0.24% H: 1.43% C: 1.43%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -10.62% | O: 0.32% H: 0.93% C: 0.38%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| 1.74% | O: -0.36% H: 0.98% C: 0.72%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -9.23% | O: -0.14% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| -0.33% | O: -0.68% H: 0.87% C: 0.1%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| -11.29% | O: -0.32% H: 0.44% C: 0.26%
america cancer immunotherapy market

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2023-12-19 (Crawled : 12:30) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K

Health Technology

| 213.7% | O: 178.08% H: 21.18% C: -1.48%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 3.94% | O: -0.5% H: 0.99% C: 0.43%
first payment astrazeneca cancer trial milestone

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published: 2023-12-18 (Crawled : 00:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 5.79% | O: 1.03% H: 1.08% C: 0.73%
breast cancer trials plus initiated

Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Published: 2023-12-06 (Crawled : 22:00) - biospace.com/
ILMN | $117.43 0.63% 0.63% 1.4M

Health Technology

| 5.07% | O: 1.4% H: 3.94% C: 0.58%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 7.09% | O: 0.73% H: 0.06% C: -1.38%
america lung conference test cancer

Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen Inc., Arrien Pharmaceuticals LLC and more among the key companies in the market - Technavio
Published: 2023-12-05 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

Health Technology

| 14.06% | O: 1.64% H: 0.0% C: -1.33%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 8.31% | O: 1.51% H: 0.13% C: -1.68%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -2.69% | O: 0.52% H: 0.18% C: -0.43%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| 9.41% | O: -0.03% H: 0.28% C: -0.41%
BAX | $39.47 -0.45% 0.0% 2.8M

Health Technology

| 10.25% | O: 0.14% H: 0.78% C: 0.22%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 15.11% | O: 0.26% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 7.09% | O: 0.73% H: 0.06% C: -1.38%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| -0.72% | O: 0.2% H: 0.2% C: -0.76%
GOOGL | News S | $154.08 -1.24% -1.25% 32M

Technology Services

| 19.45% | O: 1.97% H: 0.0% C: 0.0%
GOOG | News S | $155.7 -1.12% -1.13% 20M

Technology Services

| 19.44% | O: 1.97% H: 0.0% C: 0.0%
ADBE | News A | $465.03 -1.72% -1.75% 3M

Technology Services

| -22.78% | O: 0.97% H: 0.08% C: -2.03%
tube companies abbvie cancer pharmaceuticals therapeutics market

Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd., Amgen Inc., AstraZeneca Plc, Athenex Inc. and more among the major companies in the market- Technavio
Published: 2023-12-01 (Crawled : 23:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| Email alert Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| Email alert Add to watchlist
AZNCF | News | $138.24 -4.19% 800

Health Technology

| Email alert Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| Email alert Add to watchlist
companies astrazeneca cancer therapeutics market

Locally Advanced Pancreatic Cancer Market Report 2023-2028: Recent Advancements in Immunotherapy Inject New Hope into LAPC Market
Published: 2023-11-21 (Crawled : 23:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 8.4% | O: 0.76% H: 0.0% C: -0.05%
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| 0.93% | O: 0.56% H: 1.53% C: 1.37%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 6.64% | O: -0.89% H: 0.33% C: -0.16%
report hope cancer pancreatic immunotherapy market

Increasing Prevalence of Laryngeal Cancer Fuels Growth in Laryngeal Cancer Therapeutics Market
Published: 2023-10-27 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -11.93% | O: -18.18% H: 0.0% C: 0.0%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 8.72% | O: -1.1% H: 0.18% C: -1.98%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -12.87% | O: -15.73% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 8.11% | O: -0.42% H: 0.13% C: -1.99%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| -0.29% | O: -0.28% H: 0.15% C: -2.74%
cancer therapeutics growth market

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Published: 2023-10-23 (Crawled : 19:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 7.39% | O: -1.57% H: 1.06% C: 0.36%
breast her2 cancer trial negative

← Previous
1
2
3
4
5
6
7
8
Next →

tags : Cancer entities : Astrazeneca plc

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

tags : Cancer entities : Astrazeneca plc save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

tags : Cancer entities : Astrazeneca plc

save search